Allogene Therapeutics (ALLO) EPS (Weighted Average and Diluted) (2019 - 2026)
Allogene Therapeutics' (ALLO) quarterly EPS (Weighted Average and Diluted) came in at -$0.18 in Q1 2026, up 35.71% year-on-year from -$0.13 in Q1 2025, and down 5.88% quarter-over-quarter from -$0.17 in Q4 2025.
Allogene Therapeutics (ALLO) EPS (Weighted Average and Diluted) (2019 - 2026) Analysis & Trends
Allogene Therapeutics has disclosed EPS (Weighted Average and Diluted) across 8 years of filings, most recently posting -$0.18 for Q1 2026.
- EPS (Weighted Average and Diluted) for Q1 2026 came in at -$0.18, up 35.71% year-over-year; the trailing twelve-month figure through Mar 2026 was -$0.77 (up 37.4% YoY), and the FY2025 annual result was -$0.87, up 34.09% from the prior year.
- EPS (Weighted Average and Diluted) came in at -$0.18 for Q1 2026 at Allogene Therapeutics, down from -$0.17 in the prior quarter.
- In the past five years, EPS (Weighted Average and Diluted) ranged from a high of -$0.17 in Q4 2025 to a low of -$0.69 in Q1 2023.
- The 5-year median for EPS (Weighted Average and Diluted) is -$0.37 (2023), against an average of -$0.4.
- Across the five-year window, EPS (Weighted Average and Diluted) plunged 6900.0% in 2022 and jumped 45.1% in 2024, its largest moves.
- Allogene Therapeutics' EPS (Weighted Average and Diluted) stood at -$0.68 in 2022, then rose by 25.0% to -$0.51 in 2023, then surged by 45.1% to -$0.28 in 2024, then jumped by 39.29% to -$0.17 in 2025, then declined by 5.88% to -$0.18 in 2026.
- The last three EPS (Weighted Average and Diluted) figures came in at -$0.18 (Q1 2026), -$0.17 (Q4 2025), and -$0.19 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 3.06 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 0.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -0.61 |
| 10 | Allogene Therapeutics | 482.98 Mn | 482.98 Mn | - | -0.18 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.18 |
| Dec 31, 2025 | -0.17 |
| Sep 30, 2025 | -0.19 |
| Jun 30, 2025 | -0.23 |
| Mar 31, 2025 | -0.28 |
| Dec 31, 2024 | -0.28 |
| Sep 30, 2024 | -0.32 |
| Jun 30, 2024 | -0.35 |
| Mar 31, 2024 | -0.38 |
| Dec 31, 2023 | -0.51 |
| Sep 30, 2023 | -0.37 |
| Jun 30, 2023 | -0.54 |
| Mar 31, 2023 | -0.69 |
| Dec 31, 2022 | -0.68 |
| Sep 30, 2022 | -0.59 |
| Jun 30, 2022 | -0.56 |
| Mar 31, 2022 | -0.56 |
| Dec 31, 2021 | 0.01 |
| Sep 30, 2021 | -0.57 |
| Jun 30, 2021 | -0.53 |